An Open-label, Randomized, Controlled, 4-week Comparative Clinical Trial of Barnidipine Hydrochloride, a Calcium-channel Blocker, and Benazepril, an Angiotensin-converting Enzyme Inhibitor, in Chinese Patients with Renal Parenchymal Hypertension

Abstract

This study compared barnidipine, a calcium-channel blocker, and benazepril, an angiotensin-converting enzyme inhibitor, in 85 Chinese patients with renal parenchymal hypertension (diastolic blood pressure range 95 - 110 mmHg). Patients were randomly assigned to receive either 10 mg barnidipine or 10 mg benazepril orally daily for 4 weeks. In patients with diastolic blood pressure > 90 mmHg after 2 weeks of treatment, the dose of barnidipine or benazepril was increased by 5 or 10 mg, respectively. Both the barnidipine-treated group (n = 43) and the benazepril-treated group (n = 42) showed significant mean reductions from baseline in sitting systolic and diastolic blood pressures. The decrease in diastolic blood pressure with benazepril was significantly greater than with barnidipine treatment. Sitting heart rate was not changed by either drug. There was no significant difference in adverse events between the two groups. Barnidipine is similar to benazepril for the treatment of renal parenchymal hypertension.

Comparative Study of Barnidipine and Felodipine in Chinese Patients with Essential Hypertension

“…Barnidipine has been shown to reduce blood pressure both in patients with essential hypertension in Japan, 5 -8 Korea, 9 Europe 10 -15 and Taiwan 20 and those with renal hypertension in Japan, 23 -25 Korea 26 and China. 27 Unlike angiotensin-converting enzyme inhibitors, it is especially useful for the treatment of severe renal hypertension. Barnidipine may be regarded as a safe and effective calcium antagonist with antihypertensive actions.…”